BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
about
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions?Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanomaCombatting mucosal melanoma: recent advances and future perspectives
P2860
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@en
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@nl
type
label
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@en
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@nl
prefLabel
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@en
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
@en
P2093
Anthony Cheung
Daniele Scotto
Debra H Josephs
Giulia Pellizzari
Heather J Bax
Katie E Lacy
Kristina M Ilieva
Mano Nakamura
Matthew D Wynne
Merope Griffin
P2860
P304
78174-78192
P356
10.18632/ONCOTARGET.19836
P407
P577
2017-08-03T00:00:00Z